nodes	percent_of_prediction	percent_of_DWPC	metapath
Montelukast—Trauma—Hydrochlorothiazide—nephrolithiasis	0.0603	0.071	CcSEcCtD
Montelukast—Memory impairment—Hydrochlorothiazide—nephrolithiasis	0.0366	0.0431	CcSEcCtD
Montelukast—Vasculitis—Hydrochlorothiazide—nephrolithiasis	0.0294	0.0346	CcSEcCtD
Montelukast—Wheezing—Hydrochlorothiazide—nephrolithiasis	0.0279	0.0328	CcSEcCtD
Montelukast—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.0241	0.0283	CcSEcCtD
Montelukast—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.0235	0.0277	CcSEcCtD
Montelukast—Injury—Hydrochlorothiazide—nephrolithiasis	0.0227	0.0267	CcSEcCtD
Montelukast—Thirst—Hydrochlorothiazide—nephrolithiasis	0.0219	0.0258	CcSEcCtD
Montelukast—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.0188	0.0221	CcSEcCtD
Montelukast—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	0.0188	0.0221	CcSEcCtD
Montelukast—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.0188	0.0221	CcSEcCtD
Montelukast—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.0184	0.0216	CcSEcCtD
Montelukast—Influenza—Hydrochlorothiazide—nephrolithiasis	0.018	0.0212	CcSEcCtD
Montelukast—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.0177	0.0208	CcSEcCtD
Montelukast—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.0167	0.0197	CcSEcCtD
Montelukast—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.0161	0.019	CcSEcCtD
Montelukast—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.0159	0.0187	CcSEcCtD
Montelukast—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.0157	0.0185	CcSEcCtD
Montelukast—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.0156	0.0184	CcSEcCtD
Montelukast—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.0156	0.0184	CcSEcCtD
Montelukast—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.0151	0.0178	CcSEcCtD
Montelukast—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.0151	0.0177	CcSEcCtD
Montelukast—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.0144	0.017	CcSEcCtD
Montelukast—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.0144	0.017	CcSEcCtD
Montelukast—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.0143	0.0169	CcSEcCtD
Montelukast—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.0143	0.0168	CcSEcCtD
Montelukast—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.0136	0.016	CcSEcCtD
Montelukast—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.0121	0.0142	CcSEcCtD
Montelukast—Tremor—Hydrochlorothiazide—nephrolithiasis	0.0118	0.0138	CcSEcCtD
Montelukast—Agitation—Hydrochlorothiazide—nephrolithiasis	0.0115	0.0136	CcSEcCtD
Montelukast—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.0115	0.0135	CcSEcCtD
Montelukast—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.0111	0.0131	CcSEcCtD
Montelukast—Cough—Hydrochlorothiazide—nephrolithiasis	0.0109	0.0129	CcSEcCtD
Montelukast—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.0107	0.0126	CcSEcCtD
Montelukast—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.0107	0.0126	CcSEcCtD
Montelukast—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.0106	0.0125	CcSEcCtD
Montelukast—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.0102	0.0121	CcSEcCtD
Montelukast—Oedema—Hydrochlorothiazide—nephrolithiasis	0.0102	0.0121	CcSEcCtD
Montelukast—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.01	0.0118	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00933	0.011	CcSEcCtD
Montelukast—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00926	0.0109	CcSEcCtD
Montelukast—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00919	0.0108	CcSEcCtD
Montelukast—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.0091	0.0107	CcSEcCtD
Montelukast—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00901	0.0106	CcSEcCtD
Montelukast—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00883	0.0104	CcSEcCtD
Montelukast—Pain—Hydrochlorothiazide—nephrolithiasis	0.00876	0.0103	CcSEcCtD
Montelukast—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00837	0.00986	CcSEcCtD
Montelukast—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00813	0.00958	CcSEcCtD
Montelukast—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00809	0.00953	CcSEcCtD
Montelukast—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00809	0.00953	CcSEcCtD
Montelukast—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00754	0.00888	CcSEcCtD
Montelukast—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00735	0.00865	CcSEcCtD
Montelukast—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00724	0.00853	CcSEcCtD
Montelukast—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00701	0.00825	CcSEcCtD
Montelukast—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00677	0.00797	CcSEcCtD
Montelukast—CYSLTR1—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00663	0.0439	CbGpPWpGaD
Montelukast—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00651	0.00767	CcSEcCtD
Montelukast—Rash—Hydrochlorothiazide—nephrolithiasis	0.00646	0.0076	CcSEcCtD
Montelukast—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00645	0.0076	CcSEcCtD
Montelukast—Headache—Hydrochlorothiazide—nephrolithiasis	0.00641	0.00755	CcSEcCtD
Montelukast—SLCO2B1—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00639	0.0423	CbGpPWpGaD
Montelukast—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00608	0.00716	CcSEcCtD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00593	0.0393	CbGpPWpGaD
Montelukast—SLCO2B1—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00584	0.0387	CbGpPWpGaD
Montelukast—SLCO2B1—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00584	0.0387	CbGpPWpGaD
Montelukast—CYSLTR1—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.0048	0.0318	CbGpPWpGaD
Montelukast—SLCO2B1—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00443	0.0293	CbGpPWpGaD
Montelukast—SLCO2B1—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00443	0.0293	CbGpPWpGaD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00429	0.0284	CbGpPWpGaD
Montelukast—SLCO2B1—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00412	0.0273	CbGpPWpGaD
Montelukast—SLCO2B1—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00412	0.0273	CbGpPWpGaD
Montelukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00371	0.0246	CbGpPWpGaD
Montelukast—SLCO2B1—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00367	0.0243	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00364	0.0241	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00364	0.0241	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00325	0.0215	CbGpPWpGaD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00318	0.021	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00297	0.0197	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00297	0.0197	CbGpPWpGaD
Montelukast—CYP2A6—NRF2 pathway—SLC2A9—nephrolithiasis	0.00288	0.0191	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—RGS14—nephrolithiasis	0.0028	0.0185	CbGpPWpGaD
Montelukast—PTGS1—Biological oxidations—SLC26A1—nephrolithiasis	0.00267	0.0177	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—RGS14—nephrolithiasis	0.00254	0.0168	CbGpPWpGaD
Montelukast—CYP2A6—Biological oxidations—SLC26A1—nephrolithiasis	0.00253	0.0168	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR ligand binding—CHRM3—nephrolithiasis	0.00242	0.016	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00225	0.0149	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00225	0.0149	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR ligand binding—PTH—nephrolithiasis	0.00221	0.0147	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00209	0.0139	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00209	0.0139	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—DGKH—nephrolithiasis	0.00189	0.0125	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00186	0.0124	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00186	0.0124	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—ADCY10—nephrolithiasis	0.00177	0.0117	CbGpPWpGaD
Montelukast—CYP2C8—Biological oxidations—SLC26A1—nephrolithiasis	0.00173	0.0114	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—DGKH—nephrolithiasis	0.00172	0.0114	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—RGS14—nephrolithiasis	0.0015	0.00995	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00149	0.00988	CbGpPWpGaD
Montelukast—CYP2C9—Biological oxidations—SLC26A1—nephrolithiasis	0.00141	0.00931	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—GRHPR—nephrolithiasis	0.00139	0.00922	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00137	0.00906	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—PTH—nephrolithiasis	0.00125	0.00828	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—CHRM3—nephrolithiasis	0.00124	0.00822	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—AGXT—nephrolithiasis	0.00124	0.00822	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—PTH—nephrolithiasis	0.00114	0.00752	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—SLC26A1—nephrolithiasis	0.00105	0.00699	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—APRT—nephrolithiasis	0.00105	0.00699	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—DGKH—nephrolithiasis	0.00101	0.00672	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00101	0.00672	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.000927	0.00614	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—AQP1—nephrolithiasis	0.000751	0.00498	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CHRM3—nephrolithiasis	0.000733	0.00486	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—CHRM3—nephrolithiasis	0.00068	0.0045	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—PTH—nephrolithiasis	0.000671	0.00444	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—GRHPR—nephrolithiasis	0.000603	0.004	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—GRHPR—nephrolithiasis	0.000571	0.00378	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—AGXT—nephrolithiasis	0.000538	0.00356	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—AGXT—nephrolithiasis	0.000509	0.00337	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—APRT—nephrolithiasis	0.000457	0.00303	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—SLC26A1—nephrolithiasis	0.000457	0.00303	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—SLC26A1—nephrolithiasis	0.000432	0.00287	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—APRT—nephrolithiasis	0.000432	0.00287	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—GRHPR—nephrolithiasis	0.00039	0.00258	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—AGXT—nephrolithiasis	0.000347	0.0023	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—SPP1—nephrolithiasis	0.000337	0.00223	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—AQP1—nephrolithiasis	0.000326	0.00216	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—GRHPR—nephrolithiasis	0.000317	0.0021	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—AQP1—nephrolithiasis	0.000308	0.00204	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—APRT—nephrolithiasis	0.000295	0.00196	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—SLC26A1—nephrolithiasis	0.000295	0.00196	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CHRM3—nephrolithiasis	0.000295	0.00195	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—AGXT—nephrolithiasis	0.000283	0.00187	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—CHRM3—nephrolithiasis	0.000279	0.00185	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—APRT—nephrolithiasis	0.00024	0.00159	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—SLC26A1—nephrolithiasis	0.00024	0.00159	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—AQP1—nephrolithiasis	0.00021	0.00139	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—GRHPR—nephrolithiasis	0.000209	0.00139	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CHRM3—nephrolithiasis	0.00019	0.00126	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—AGXT—nephrolithiasis	0.000186	0.00124	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—AQP1—nephrolithiasis	0.000171	0.00113	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	0.000159	0.00105	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—APRT—nephrolithiasis	0.000159	0.00105	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CHRM3—nephrolithiasis	0.000155	0.00103	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—AQP1—nephrolithiasis	0.000113	0.000749	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—CHRM3—nephrolithiasis	0.000102	0.000677	CbGpPWpGaD
